STOCK TITAN

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Amphastar Pharmaceuticals (NASDAQ:AMPH) reported Q3 2024 financial results with net revenues of $191.2 million, up 6% year-over-year. The company achieved GAAP net income of $40.4 million ($0.78 per share) and adjusted non-GAAP net income of $49.6 million ($0.96 per share). BAQSIMI® contributed significantly with $40.4 million in direct sales, while Primatene MIST® sales increased 5% to $26.1 million. The Board authorized a $50 million increase to the share buyback program. Operating cash flow for the first nine months was $184.4 million.

Amphastar Pharmaceuticals (NASDAQ:AMPH) ha riportato i risultati finanziari del terzo trimestre 2024 con ricavi netti di 191,2 milioni di dollari, in aumento del 6% rispetto all'anno precedente. L'azienda ha registrato un reddito netto GAAP di 40,4 milioni di dollari (0,78 dollari per azione) e un reddito netto non-GAAP rettificato di 49,6 milioni di dollari (0,96 dollari per azione). BAQSIMI® ha contribuito in modo significativo con vendite dirette di 40,4 milioni di dollari, mentre le vendite di Primatene MIST® sono aumentate del 5% a 26,1 milioni di dollari. Il Consiglio ha autorizzato un aumento di 50 milioni di dollari al programma di riacquisto delle azioni. Il flusso di cassa operativo per i primi nove mesi è stato di 184,4 milioni di dollari.

Amphastar Pharmaceuticals (NASDAQ:AMPH) reportó los resultados financieros del tercer trimestre de 2024, con ingresos netos de 191,2 millones de dólares, un aumento del 6% en comparación con el año anterior. La compañía logró un ingreso neto GAAP de 40,4 millones de dólares (0,78 dólares por acción) y un ingreso neto ajustado no GAAP de 49,6 millones de dólares (0,96 dólares por acción). BAQSIMI® contribuyó significativamente con 40,4 millones de dólares en ventas directas, mientras que las ventas de Primatene MIST® aumentaron un 5% a 26,1 millones de dólares. La Junta autorizó un aumento de 50 millones de dólares en el programa de recompra de acciones. El flujo de caja operativo para los primeros nueve meses fue de 184,4 millones de dólares.

암파스타 제약 (NASDAQ:AMPH)는 2024년 3분기 재무 결과를 보고하며 순수익이 1억 9120만 달러로 지난해 대비 6% 증가했다고 발표했습니다. 회사는 GAAP 기준 순이익 4040만 달러 (주당 0.78 달러) 및 조정된 비-GAAP 순이익 4960만 달러 (주당 0.96 달러)를 달성했습니다. BAQSIMI®는 4040만 달러의 직접 판매로 큰 기여를 하였고, Primatene MIST®의 판매는 5% 증가하여 2610만 달러에 달했습니다. 이사회는 주식 매입 프로그램에 5000만 달러의 증가를 승인했습니다. 첫 9개월 동안의 운영 현금 흐름은 1억 8440만 달러였습니다.

Amphastar Pharmaceuticals (NASDAQ:AMPH) a annoncé les résultats financiers du troisième trimestre 2024 avec des revenus nets de 191,2 millions de dollars, en hausse de 6 % par rapport à l'année précédente. L'entreprise a réalisé un bénéfice net GAAP de 40,4 millions de dollars (0,78 dollar par action) et un bénéfice net ajusté non-GAAP de 49,6 millions de dollars (0,96 dollar par action). BAQSIMI® a contribué de manière significative avec 40,4 millions de dollars en ventes directes, tandis que les ventes de Primatene MIST® ont augmenté de 5 % pour atteindre 26,1 millions de dollars. Le conseil d'administration a autorisé une augmentation de 50 millions de dollars du programme de rachat d'actions. Le flux de trésorerie d'exploitation pour les neuf premiers mois s'élevait à 184,4 millions de dollars.

Amphastar Pharmaceuticals (NASDAQ:AMPH) hat die finanziellen Ergebnisse für das dritte Quartal 2024 veröffentlicht, mit einem Nettoumsatz von 191,2 Millionen Dollar, was einem Anstieg von 6% im Vergleich zum Vorjahr entspricht. Das Unternehmen erzielte einen GAAP-Nettoertrag von 40,4 Millionen Dollar (0,78 Dollar pro Aktie) sowie einen angepasstes Non-GAAP-Nettoergebnis von 49,6 Millionen Dollar (0,96 Dollar pro Aktie). BAQSIMI® leistete mit 40,4 Millionen Dollar an Direktverkäufen einen wesentlichen Beitrag, während die Verkäufe von Primatene MIST® um 5% auf 26,1 Millionen Dollar stiegen. Der Vorstand genehmigte eine Erhöhung um 50 Millionen Dollar für das Aktienrückkaufprogramm. Der operative Cashflow für die ersten neun Monate betrug 184,4 Millionen Dollar.

Positive
  • Net revenues increased 6% YoY to $191.2 million
  • BAQSIMI® generated $40.4 million in direct sales
  • Primatene MIST® sales grew 5% to $26.1 million
  • Strong operating cash flow of $184.4 million for nine months
  • $50 million increase in share buyback program authorization
Negative
  • GAAP net income decreased from $49.2M to $40.4M YoY
  • Gross margin declined from 60.0% to 53.3%
  • Enoxaparin sales decreased 27% to $5.6 million
  • R&D expenses increased 26% to $21.1 million
  • Other revenues decreased 92% to $2.4 million

Insights

Q3 results show mixed performance with $191.2M revenue (6% YoY growth) but declining margins. BAQSIMI emerges as a key growth driver with $40.4M in direct sales. Gross margin compressed to 53.3% from 60% due to higher costs and inventory adjustments. Strong operating cash flow of $184.4M YTD demonstrates solid operational execution.

Pipeline developments are promising with 4 ANDAs targeting $2.4B market and biosimilars targeting $8B market. The $50M share buyback expansion shows management's confidence. However, rising R&D costs (26% increase) and declining sales in legacy products like Enoxaparin (-27%) and Glucagon (-9%) warrant attention.

Product portfolio transition shows strategic shift toward higher-value segments. Primatene MIST trending toward $100M annual sales target represents successful consumer product strategy. The expansion into Canadian markets with epinephrine pre-filled syringes indicates geographic growth potential.

R&D investment in insulin pipeline and biosimilars aligns with high-growth market opportunities. However, increased operating expenses and cost pressures could impact near-term profitability. The delayed $2-4M revenue recognition due to Hurricane Helene suggests potential vulnerability to external disruptions.

Reports Net Revenues of $191.2 Million for the Three Months Ended September 30, 2024

RANCHO CUCAMONGA, CA / ACCESSWIRE / November 6, 2024 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended September 30, 2024.

Third quarter Highlights

  • Net revenues of $191.2 million for the third quarter

  • GAAP net income of $40.4 million, or $0.78 per share, for the third quarter

  • Adjusted non-GAAP net income of $49.6 million, or $0.96 per share, for the third quarter

Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Amphastar has continued its growth this quarter, highlighted by sales, particularly from BAQSIMI®, which has become a cornerstone in our portfolio, and Primatene MIST®, which is trending toward our goal of $100 million in sales per year. Looking forward, we will focus on positioning our Company towards sustainable, long-term growth by pivoting to high-value and high-growth areas, particularly centered on developing proprietary products and biosimilars, which we expect will allow us to leverage our R&D expertise and technology."

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

(in thousands, except per share data)

Net revenues

$

191,214

$

180,556

$

545,444

$

466,290

GAAP net income

$

40,429

$

49,222

$

121,555

$

101,378

Adjusted non-GAAP net income*

$

49,585

$

61,898

$

153,569

$

128,823

GAAP diluted EPS

$

0.78

$

0.91

$

2.32

$

1.91

Adjusted non-GAAP diluted EPS*

$

0.96

$

1.15

$

2.94

$

2.43

____________________________________

* Adjusted non-GAAP net income and adjusted non-GAAP diluted EPS are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

Third quarter Results

Three Months Ended

September 30,

Change

2024

2023

Dollars

%

(in thousands)

Product revenues:

BAQSIMI®

$

40,409

$

-

$

40,409

N/A

Glucagon

26,792

29,514

(2,722

)

(9

)%

Primatene MIST®

26,055

24,834

1,221

5

%

Epinephrine

21,341

20,199

1,142

6

%

Lidocaine

15,884

15,522

362

2

%

Phytonadione

11,721

7,449

4,272

57

%

Enoxaparin

5,615

7,702

(2,087

)

(27

)%

Naloxone

4,037

4,715

(678

)

(14

)%

Other finished pharmaceutical products

35,503

37,730

(2,227

)

(6

)%

Total finished pharmaceutical products net revenues

$

187,357

$

147,665

$

39,692

27

%

API

1,462

4,190

(2,728

)

(65

)%

Other revenues

2,395

28,701

(26,306

)

(92

)%

Total net revenues

$

191,214

$

180,556

$

10,658

6

%

Changes in product revenues as compared to the third quarter of the prior year were primarily driven by:

  • BAQSIMI® revenues consisting of $40.4 million in sales made by the Company directly to its customers, which are recorded as part of product revenues, net, and $6.4 million in sales made by Eli Lilly & Company, or Lilly, on behalf of the Company under a Transition Services Agreement, or TSA, which resulted in a net payment to the Company of $2.4 million after deducting the cost of sales and other expenses and was recorded in other revenues

  • Glucagon sales decreased due to a decrease in unit volumes as a result of a move to ready to use glucagon products such as BAQSIMI®, as well as a decrease in average selling price

  • Primatene MIST® sales increased primarily due to an increase in unit volumes

  • Epinephrine sales increased primarily due to sales of epinephrine pre-filled syringes in Canada, which we began this quarter

  • The increase in sales of phytonadione was primarily due to an increase in unit volume, as a result of an increase in demand during the quarter

  • Enoxaparin and naloxone sales decreased primarily due to a decrease in unit volumes

  • Other finished pharmaceutical product sales changes were primarily due to:

    • Lower unit sales of atropine and calcium chloride, as a result of other suppliers returning to their historical distribution levels

    • These decreases were partially offset by:

      • Higher unit volumes of sodium bicarbonate due to an increase in capacity at our subsidiary, International Medication Systems, Limited

      • The launch of albuterol in August 2024

Between $2.0 million and $4.0 million in sales expected to be recognized in the third quarter were not recognized due to delayed shipments caused by the aftermath of Hurricane Helene. Revenues for these shipments are expected to be recognized in the fourth quarter.

Three Months Ended

September 30,

Change

2024

2023

Dollars

%

(in thousands)

Net revenues

$

191,214

$

180,556

$

10,658

6

%

Cost of revenues

89,273

72,153

17,120

24

%

Gross profit

$

101,941

$

108,403

$

(6,462

)

(6

)%

as % of net revenues

53.3%

60.0%

Changes in the cost of revenues and gross margin were primarily driven by:

  • Increased labor costs and certain component costs, as well as charges included in cost of revenues to adjust our inventory and related purchase commitments to their net realizable value

  • Decrease in other revenues related to Lilly's sales of BAQSIMI® under the TSA, which are recorded net of cost of sales and other expenses as we assumed distribution of BAQSIMI® to our customers and are now recording those sales in product revenues and cost of sales separately

  • This was partially offset by:

    • Increase in sales of Primatene MIST® and epinephrine, which are higher-margin products

Three Months Ended

September 30,

Change

2024

2023

Dollars

%

(in thousands)

Selling, distribution, and marketing

$

8,995

$

6,407

$

2,588

40

%

General and administrative

14,821

12,654

2,167

17

%

Research and development

21,077

16,664

4,413

26

%

  • Selling, distribution, and marketing expenses increased primarily due to the expenses related to the expansion of our sales and marketing efforts related to BAQSIMI®

  • General and administrative expenses increased primarily due to an increase in salary and personnel-related expenses and expenses related to BAQSIMI®

  • Research and development expenses increased due to expenditure on raw materials and components for our insulin pipeline products, as well as an increase in salary and personnel-related expenses, which was partially offset by a decrease in clinical trial expenses due to the timing of clinical trials

Three Months Ended

September 30,

Change

2024

2023

Dollars

%

(in thousands)

Non-operating income (expenses)

Interest income

$

2,427

$

1,202

$

1,225

102

%

Interest expense

(6,698

)

(13,702

)

7,004

(51

)%

Other income (expenses), net

(5,094

)

3,459

(8,553

)

(247

)%

Total non-operating income (expenses), net

$

(9,365

)

$

(9,041

)

$

(324

)

4

%

The change in non-operating income (expenses), net is primarily a result of:

  • An increase in interest income resulting from an increase in cash and investments

  • A decrease in interest expense was primarily due to the $250.0 million repayment of the principal balance of the Wells Fargo Term Loan in September 2023, along with the write-off of unamortized debt issuance costs related to the Term Loan in 2023

  • A change to other income (expenses), net primarily as a result of foreign currency fluctuation, as well as mark-to-market adjustments relating to our interest rate swap contracts

Cash flow provided by operating activities for the nine months ended September 30, 2024, was $184.4 million.

Share Buyback Program

On November 4, 2024, the Company's Board of Directors authorized a $50 million increase to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.

Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws.

The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.

Pipeline Information

The Company currently has four abbreviated new drug applications ("ANDAs") on file with the U.S. Food and Drug Administration (the "FDA") targeting products with a market size of over $2.4 billion, four biosimilar products in development targeting products with a market size of over $8 billion, and three generic products in development targeting products with a market size of approximately $2 billion. This market information is based on IQVIA data for the 12 months ended September 30, 2024. The Company is developing multiple proprietary products with injectable and intranasal dosage forms.

Amphastar's Chinese subsidiary, Amphastar Nanjing Pharmaceuticals, Co., Ltd. ("ANP"), currently has multiple Drug Master Files ("DMFs") on file with the FDA and is developing several additional DMFs.

Company Information

Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com.

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar®, BAQSIMI®, Primatene MIST®, REXTOVYTM, Amphadase®, and Cortrosyn®, are the property of Amphastar.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) and (ii) Adjusted non-GAAP diluted EPS, which exclude amortization expense, share-based compensation, impairment charges, expenses related to our acquisition of BAQSIMI®, certain debt issuance costs, legal settlements, and other one-time events in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Conference Call Information

The Company will hold a conference call to discuss its financial results today, November 6, 2024, at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, ten minutes before the conference.

The call can also be accessed on the Investors page on the Company's website at www.amphastar.com.

Forward-Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance and business trends, our future growth, sales and marketing of our products, market size and expansion, product portfolio, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, the timing and results of clinical trials, the benefits of the acquisition of BAQSIMI®, including its potential for continued revenue growth, the success of our integration of BAQSIMI®, the transition of our pipeline towards branded products, proprietary products, and biosimilars, our ability to leverage our existing expertise and technology, and other future events. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on February 29, 2024, in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2024, filed with the SEC on May 10, 2024, and in our Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the SEC on August 9, 2024. In particular, there can be no guarantee that our pivoting towards high-value and high-growth areas market will be successful, that demand will be sufficient for us to meet our sales goal for Primatene MIST® or that we will continue to experience significant sales of BAQSIMI®. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact Information:

Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 476-3416

Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

Net revenues:

Product revenues, net

$

188,819

$

151,855

$

525,836

$

437,589

Other revenues

2,395

28,701

19,608

28,701

Total net revenues

191,214

180,556

545,444

466,290

Cost of revenues

89,273

72,153

258,237

211,309

Gross profit

101,941

108,403

287,207

254,981

Operating expenses:

Selling, distribution, and marketing

8,995

6,407

27,378

20,234

General and administrative

14,821

12,654

43,782

38,418

Research and development

21,077

16,664

55,772

53,322

Total operating expenses

44,893

35,725

126,932

111,974

Income from operations

57,048

72,678

160,275

143,007

Non-operating income (expenses):

Interest income

2,427

1,202

8,320

3,156

Interest expense

(6,698

)

(13,702

)

(23,918

)

(17,702

)

Other income (expenses), net

(5,094

)

3,459

1,125

1,553

Total non-operating income (expenses), net

(9,365

)

(9,041

)

(14,473

)

(12,993

)

Income before income taxes

47,683

63,637

145,802

130,014

Income tax provision

7,254

14,025

23,674

27,160

Net income before equity in losses of unconsolidated affiliate

40,429

49,612

122,128

102,854

Equity in losses of unconsolidated affiliate

-

(390

)

(573

)

(1,476

)

Net income

$

40,429

$

49,222

$

121,555

$

101,378

Net income per share:

Basic

$

0.83

$

1.01

$

2.50

$

2.10

Diluted

$

0.78

$

0.91

$

2.32

$

1.91

Weighted-average shares used to compute net income per share:

Basic

48,621

48,701

48,580

48,368

Diluted

51,862

53,921

52,307

52,997

Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands, except share data)

September 30,

December 31,

2024

2023

(unaudited)

ASSETS

Current assets:

Cash and cash equivalents

$

192,116

$

144,296

Restricted cash

235

235

Short-term investments

58,375

112,510

Restricted short-term investments

2,200

2,200

Accounts receivable, net

139,635

114,943

Inventories

130,316

105,833

Income tax refunds and deposits

5,349

526

Prepaid expenses and other assets

17,723

9,057

Total current assets

545,949

489,600

Property, plant, and equipment, net

295,384

282,746

Finance lease right-of-use assets

426

564

Operating lease right-of-use assets

31,708

32,333

Investment in unconsolidated affiliate

-

527

Goodwill and intangible assets, net

594,796

613,295

Long-term investments

-

14,685

Other assets

23,663

25,910

Deferred tax assets

53,252

53,252

Total assets

$

1,545,178

$

1,512,912

LIABILITIES AND STOCKHOLDERS' EQUITY

Current liabilities:

Accounts payable and accrued liabilities

$

153,268

$

93,366

Accrued payments for BAQSIMI®

-

126,090

Income taxes payable

1,281

1,609

Current portion of long-term debt

252

436

Current portion of operating lease liabilities

4,209

3,906

Total current liabilities

159,010

225,407

Long-term reserve for income tax liabilities

6,066

6,066

Long-term debt, net of current portion and unamortized debt issuance costs

596,446

589,579

Long-term operating lease liabilities, net of current portion

28,941

29,721

Other long-term liabilities

27,037

22,718

Total liabilities

817,500

873,491

Commitments and contingencies

Stockholders' equity:

Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding

-

-

Common stock: par value $0.0001; 300,000,000 shares authorized; 60,690,076 and 48,372,997 shares issued and outstanding, respectively, as of September 30, 2024 and 59,390,194 and 48,068,881 shares issued and outstanding, respectively, as of December 31, 2023

6

6

Additional paid-in capital

496,427

486,056

Retained earnings

530,823

409,268

Accumulated other comprehensive loss

(8,821

)

(8,478

)

Treasury stock

(290,757

)

(247,431

)

Total equity

727,678

639,421

Total liabilities and stockholders' equity

$

1,545,178

$

1,512,912

Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)

Three Months Ended

Nine Months Ended

September 30,

September 30,

2024

2023

2024

2023

GAAP net income

$

40,429

$

49,222

$

121,555

$

101,378

Adjusted for:

Intangible asset amortization

6,179

6,168

18,539

6,651

Share-based compensation

5,596

4,644

18,736

15,620

Impairment of long-lived assets

-

474

-

3,174

Expenses related to BAQSIMI® acquisition

-

2,182

3,651

3,682

Debt issuance costs

-

3,019

-

6,043

Income tax provision on pre-tax adjustments

(2,619

)

(3,811

)

(8,912

)

(7,725

)

Adjusted non-GAAP net income

$

49,585

$

61,898

$

153,569

$

128,823

Adjusted non-GAAP net income per share:

Basic

$

1.02

$

1.27

$

3.16

$

2.66

Diluted

$

0.96

$

1.15

$

2.94

$

2.43

Weighted-average shares used to compute adjusted non-GAAP net income per share:

Basic

48,621

48,701

48,580

48,368

Diluted

51,862

53,921

52,307

52,997

Three Months Ended September 30, 2024

Selling,

General

Research

Non-operating

Cost of

distribution

and

and

(expenses)

Income

revenue

and marketing

administrative

development

income, net

tax provision

GAAP

$

89,273

$

8,995

$

14,821

$

21,077

$

(9,365

)

$

7,254

Intangible asset amortization

(6,159

)

-

(1

)

(19

)

-

-

Share-based compensation

(1,133

)

(249

)

(3,710

)

(504

)

-

-

Income tax provision on pre-tax adjustments

-

-

-

-

-

2,619

Non-GAAP

$

81,981

$

8,746

$

11,110

$

20,554

$

(9,365

)

$

9,873

Three Months Ended September 30, 2023

Selling,

General

Research

Non-operating

Cost of

distribution

and

and

(expenses)

Income

revenue

and marketing

administrative

development

income, net

tax provision

GAAP

$

72,153

$

6,407

$

12,654

$

16,664

$

(9,041

)

$

14,025

Intangible asset amortization

(6,149

)

-

34

(53

)

-

-

Share-based compensation

(1,004

)

(213

)

(2,975

)

(452

)

-

-

Impairment of long-lived assets

(470

)

-

(4

)

-

-

-

Expenses related to BAQSIMI® acquisition

-

-

(357

)

-

1,825

-

Debt issuance costs

-

-

-

-

3,019

-

Income tax provision on pre-tax adjustments

-

-

-

-

-

3,811

Non-GAAP

$

64,530

$

6,194

$

9,352

$

16,159

$

(4,197

)

$

17,836

Nine Months Ended September 30, 2024

Selling,

General

Research

Non-operating

Cost of

distribution

and

and

(expenses)

Income

revenue

and marketing

administrative

development

income, net

tax provision

GAAP

$

258,237

$

27,378

$

43,782

$

55,772

$

(14,473

)

$

23,674

Intangible asset amortization

(18,479

)

-

(4

)

(56

)

-

-

Share-based compensation

(4,583

)

(777

)

(11,239

)

(2,137

)

-

-

Expenses related to BAQSIMI® acquisition

-

-

-

-

3,651

-

Income tax provision on pre-tax adjustments

-

-

-

-

-

8,912

Non-GAAP

$

235,175

$

26,601

$

32,539

$

53,579

$

(10,822

)

$

32,586

Nine Months Ended September 30, 2023

Selling,

General

Research

Non-operating

Cost of

distribution

and

and

(expenses)

Income

revenue

and marketing

administrative

development

income, net

tax provision

GAAP

$

211,309

$

20,234

$

38,418

$

53,322

$

(12,993

)

$

27,160

Intangible asset amortization

(6,582

)

-

(16

)

(53

)

-

-

Share-based compensation

(3,868

)

(649

)

(9,323

)

(1,780

)

-

-

Impairment of long-lived assets

(3,170

)

-

(4

)

-

-

-

Expenses related to BAQSIMI® acquisition

-

-

(1,857

)

-

1,825

-

Debt issuance costs

-

-

-

-

6,043

-

Income tax provision on pre-tax adjustments

-

-

-

-

-

7,725

Non-GAAP

$

197,689

$

19,585

$

27,218

$

51,489

$

(5,125

)

$

34,885

SOURCE: Amphastar Pharmaceuticals, Inc.



View the original press release on accesswire.com

FAQ

What was Amphastar's (AMPH) revenue in Q3 2024?

Amphastar reported net revenues of $191.2 million in Q3 2024, representing a 6% increase from $180.6 million in Q3 2023.

How much did BAQSIMI contribute to Amphastar's (AMPH) Q3 2024 revenue?

BAQSIMI generated $40.4 million in direct sales for Amphastar in Q3 2024, plus an additional $6.4 million in sales through Eli Lilly under a Transition Services Agreement.

What was Amphastar's (AMPH) earnings per share in Q3 2024?

Amphastar reported GAAP earnings of $0.78 per share and adjusted non-GAAP earnings of $0.96 per share in Q3 2024.

How much did Amphastar (AMPH) increase its share buyback program in November 2024?

Amphastar's Board of Directors authorized a $50 million increase to the Company's share buyback program on November 4, 2024.

Amphastar Pharmaceuticals, Inc.

NASDAQ:AMPH

AMPH Rankings

AMPH Latest News

AMPH Stock Data

2.12B
37.71M
22.41%
74.81%
8.98%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States of America
RANCHO CUCAMONGA